Skip to main content

Table 4 Factors associated with treatment success by 24 months among patients who were diagnosed with RR-TB between July 2011–June 2012 or between July 2013–July 2014 and who initiated DR-TB treatment in COJ (n = 537)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

 

n/N

%

RR

95% CI

Adjusted RR

95% CI

Gender

 Female

75/258

29.1

Ref

Ref

Ref

Ref

 Male

86/279

30.8

1.09

(0.79–1.49)

1.01

(0.74–1.41)

Age, years

  < 30

31/138

22.5

Ref

Ref

Ref

Ref

 30–45

93/282

32.9

1.56

(1.02–2.37)

1.46

(0.94–2.25)

  ≥ 45

37/117

31.6

1.46

(0.89–2.38)

1.43

(0.86–2.37)

DR-TB classification

 RR-TB by Xpert MTB/RIF

96/237

40.5

4.36

(2.60–7.30)

4.31

(2.55–7.29)

 RIF mono-resistant TB

47/109

43.1

4.76

(2.70–8.36)

4.46

(2.07–7.95)

 MDR-TB

18/191

9.4

Ref

Ref

Ref

Ref

HIV status at initiation

 HIV negative

14/61

22.1

0.58

(0.32–1.05)

0.75

(0.47–1.20)

 HIV positive on ART

120/351

33.4

Ref

Ref

Ref

Ref

 HIV positive not on ART

16/77

19.5

0.6

(0.36–1.02)

0.73

(0.43–1.25)

 HIV status unknown

11/48

22.9

0.64

(0.33–1.21)

0.76

(0.43–1.24)

Registration year

 2011

19/55

34.5

Ref

Ref

Ref

Ref

 2012

33/108

30.6

0.88

(0.50–1.56)

0.88

(0.49–1.56)

 2013

49/166

29.5

0.81

(0.47–1.37)

0.74

(0.43–1.28)

 2014

60/211

28.4

0.84

(0.50–1.41)

0.83

(0.49–1.41)

Time to treatment initiation

 Without delay

70/186

37.6

Ref

Ref

Ref

Ref

 Delayed (deferred)

85/332

25.6

0.97

(0.71–1.33)

0.94

(0.66–1.33)

  1. RR Relative Risk, CI Confidence interval, RR-TB Rifampicin resistant TB, MTB Mycobacterium tuberculosis, MDR-TB Multi-drug resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis; DR-TB drug resistant TB, ART antiretroviral therapy, RIF rifampicin p < 0.05 bold